Clinical effect of <italic style="font-style: italic">Shenyuan Pills</italic> on coronary heart disease patients after PCI and its impact on inflammatory responses

TAN Yupei; LIU Hongxu; ZHOU Qi; WANG Wei; HUANG Ximan; CHE Fangyuan

doi:10.16025/j.1674-1307.2025.12.002

您当前的位置：

首页 >

文章列表页 >

Clinical effect of Shenyuan Pills on coronary heart disease patients after PCI and its impact on inflammatory responses

更新时间：2026-01-24

- Clinical effect of Shenyuan Pills on coronary heart disease patients after PCI and its impact on inflammatory responses
- Beijing Journal of Traditional Chinese Medicine Vol. 44, Issue 12, Pages: 1510-1514(2025)
- 作者机构：
  
  1.北京中医医院顺义医院心血管内科，北京 101399
  2.首都医科大学附属北京中医医院心血管内科，北京 100010
  3.中国中医科学院望京医院心血管内科，北京 100102
- 作者简介：
- 基金信息：
- DOI：10.16025/j.1674-1307.2025.12.002
  CLC：
- Received：22 June 2024，
  
  Published：25 December 2025
- 稿件说明：
移动端阅览
谭玉培，刘红旭，周琦，等.参元丹对冠心病PCI术后患者的应用效果及炎症反应的影响观察［J］.北京中医药，2025，44（12）：1510-1514.

TAN Yupei,LIU Hongxu,ZHOU Qi,et al.Clinical effect of Shenyuan Pills on coronary heart disease patients after PCI and its impact on inflammatory responses[J]. Beijing Journal of Traditional Chinese Medicine,2025,44(12):1510-1514.
谭玉培，刘红旭，周琦，等.参元丹对冠心病PCI术后患者的应用效果及炎症反应的影响观察［J］.北京中医药，2025，44（12）：1510-1514. DOI： 10.16025/j.1674-1307.2025.12.002.

TAN Yupei,LIU Hongxu,ZHOU Qi,et al.Clinical effect of Shenyuan Pills on coronary heart disease patients after PCI and its impact on inflammatory responses[J]. Beijing Journal of Traditional Chinese Medicine,2025,44(12):1510-1514. DOI： 10.16025/j.1674-1307.2025.12.002.

摘要

目的

观察参元益气活血胶囊（又名参元丹）对冠心病经皮冠状动脉介入治疗（PCI）术后患者的应用效果及其对炎症介质水平的影响。

方法

选择2019年6月—2023年6月首都医科大学附属北京中医医院心血管内科行PCI术的患者68例，采用随机数字表法将患者分为观察组、对照组，各34例。2组均给予西医常规治疗，观察组于术前3 d开始服用参元丹；对照组于术前3 d开始服用中药安慰剂。均4粒/次，3次/d，连续服用至术后3 d。对比2组治疗前后中医证候积分、血清超敏C反应蛋白（hs-CRP）、单核细胞趋化因子-1（MCP-1）、肿瘤坏死因子α（TNF-α）水平，以及安全性。

结果

治疗后，2组中医证候积分均较治疗前降低（

0.05），且观察组低于对照组（

0.05）。术后4 h、24 h、72 h，2组hs-CRP、MCP-1、TNF-α水平均较治疗前升高（

0.05）。术后24 h、72 h，观察组hs-CRP水平低于对照组（

0.05）；术后4 h、24 h，观察组MCP-1水平低于对照组（

0.05）；术后4 h，观察组TNF-α水平低于对照组（

0.05）。治疗期间，2组患者均未发生不良反应。

结论

参元丹能改善冠心病患者PCI术后临床症状，减轻炎症反应，且无明显不良反应。

Abstract

Objective

To observe the clinical efficacy of

Shenyuan Yiqi Huoxue Capsules

（also known as

Shenyuan Pills

） in patients with coronary heart disease （CHD） after percutaneous coronary intervention （PCI） and its effect on inflammatory factor levels.

Method

A total of 68 patients undergoing PCI at the Department of Cardiovascular Medicine， Beijing Hospital of Traditional Chinese Medicine， Capital Medical University， from June 2019 to June 2023 were enrolled. According to the random number table method， patients were divided into an observation group and a control group， with 34 cases in each group. Both groups received conventional Western medicine treatment. The observation group received

Shenyuan Pills

starting 3 days before PCI， while the control group received a placebo over the same period. The dosage was 4 capsules per time， 3 times daily， continuously until 3 days postoperatively. Traditional Chinese medicine （TCM） syndrome scores and serum levels of hypersensitive C-reactive protein （hs-CRP）， monocyte chemoattractant protein-1 （MCP-1）， and tumor necrosis factor-α （TNF-α）， as well as safety， were compared between the t

wo groups.

Results

After treatment， TCM syndrome scores decreased significantly in both groups compared with baseline （

0.05）， and the observation group was lower than the control group （

0.05）. At 4， 24， and 72 hours postoperatively， hs-CRP， MCP-1， and TNF-α levels increased in both groups compared with preoperative levels （

0.05）. At 24 and 72 hours postoperatively， hs-CRP levels in the observation group were lower than in the control group （

0.05）； at 4 and 24 hours postoperatively， MCP-1 levels in the observation group were lower than in the control group （

0.05）； at 4 hours postoperatively， TNF-α levels in the observation group were lower than in the control group （

0.05）. No adverse reactions occurred in either group during treatment.

Conclusion

Shenyuan Pills

can improve clinical symptoms in CHD patients after PCI， reduce inflammatory responses， and is safe with no significant adverse reactions.

关键词

Keywords

references

国家卫生计生委合理用药专家委员会 , 中国药师协会 . 冠心病合理用药指南(第2版) [J ] . 中国医学前沿杂志（电子版）, 2018 , 10 ( 6 ): 1 - 130 .

世界中医药联合会心血管病专业委员会 , 中国中西医结合学会心血管病专业委员会 , 中华中医药学会介入心脏病学会 , 等 . 冠状动脉血运重建术后心绞痛中西医结合诊疗指南 [J ] . 中国中西医结合杂志 , 2020 , 40 ( 11 ): 1298 - 1307 .

BEN-YEHUDA O , KAZI DS , BONAFEDE M , et al . Angina and associated healthcare costs following percutaneous coronary intervention: a real-world analysis from a multi-payer database [J ] . Catheter Cardiovasc Interv , 2016 , 88 ( 7 ): 1017 - 1024 .

邢文龙 , 刘红旭 , 尚菊菊 , 等 . 中医药干预PCI围手术期心肌损伤随机对照临床试验的系统综述 [J ] . 北京中医药 , 2017 , 36 ( 12 ): 1072 - 1075 .

李爱勇 , 刘红旭 , 李峙宝 , 等 . 参元丹对不稳定型心绞痛气虚血瘀证患者药物洗脱球囊介入术后炎症因子影响观察 [J ] . 北京中医药 , 2022 , 41 ( 12 ): 1430 - 1432 .

牛芊 , 邢文龙 , 刘红旭 . 益气逐瘀法治疗冠心病基础与临床研究进展 [J ] . 世界中医药 , 2018 , 13 ( 8 ): 1817 - 1821 .

TONG T , YANG Z , CHEN J , et al . Protective effects of shen-yuan-dan capsule against ischemia/reperfusion injury in cardiomyocytes by alleviating endoplasmic reticulum stress [J ] . Evid Based Complement Alternat Med , 2022 : 7775876 .

LI X , ZHANG Y , LIU H , et al . A randomized, placebo-controlled, double-blind trial to evaluate efficacy and safety of Shen-Yuan-Dan capsules, a traditional Chinese medicine, for treatment of peri-procedure myocardial injury following percutaneous coronary intervention [J ] . Complement Ther Med , 2022 , 69 : 102841 .

ANDERSON JL , ADAMS CD , ANTMAN EM , et al . 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American college of cardiology foundation/American heart association task force on practice guidelines [J ] . J Am Coll Cardiol , 2013 , 61 ( 23 ): e179-347 .

中华医学会心血管病学分会介入心脏病学组 , 中国医师协会心血管内科医师分会血栓防治专业委员会 , 中华心血管病杂志编辑委员会 . 中国经皮冠状动脉介入治疗指南（2016） [J ] . 中华心血管病杂志 , 2016 , 44 ( 5 ): 382 - 400 .

国家技术监督局 . 中医临床诊疗术语第2部分：证候部分： GB/T 16751.2-2021 [S ] . 北京：中国标准出版社， 2021 .

郑筱萸 . 中药新药临床研究指导原则（试行） [M ] . 北京：中国医药科技出版社 , 2002 : 361 .

任雪玉 , 刘慧清 , 李颖妃 , 等 . 芪参丹芍颗粒治疗冠心病稳定性心绞痛气虚血瘀证的临床疗效观察 [J ] . 北京中医药 , 2023 , 42 ( 6 ): 616 - 620 .

牛涣宁 , 况松桃 , 李思耐 , 等 . 基于文献计量学分析从痰论治冠心病的方药规律 [J ] . 北京中医药 , 2023 , 42 ( 1 ): 87 - 89 .

尚菊菊 , 李爱勇 , 杨洪志 , 等 . 参元丹药理预适应对大鼠缺血再灌注心肌梗死面积、蛋白激酶C及热休克蛋白70的影响 [J ] . 中华中医药杂志 , 2011 , 26 ( 8 ): 1730 - 1733 .

刘红旭 , 李爱勇 , 解欣然 , 等 . 参元丹后处理对心肌缺血/再灌注大鼠血清MDA、SOD水平的影响 [J ] . 微循环学杂志 , 2011 , 21 ( 1 ): 1 - 2,5 .

李爱勇 , 张玉灵 , 邢文龙 , 等 . 参元益气活血胶囊对不稳定型心绞痛气虚血瘀证患者择期PCI围术期ACE2的影响 [J ] . 世界中医药 , 2017 , 12 ( 2 ): 243 - 246 .

LI H , SUN K , ZHAO R , et al . Inflammatory biomarkers of coronary heart disease [J ] . Front Biosci (Schol Ed) , 2018 , 10 ( 1 ): 185 - 196 .

SABATINE MS , MORROW DA , JABLONSKI KA , et al . Prognostic significance of the centers for disease control/American heart association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease [J ] . Circulation , 2007 , 115 ( 12 ): 1528 - 1536 .

AREFIEVA TI , KUKHTINA NB , ANTONOVA OA , et al . MCP-1-stimulated chemotaxis of monocytic and endothelial cells is dependent on activation of different signaling cascades [J ] . Cytokine , 2005 , 31 ( 6 ): 439 - 446 .

罗南萍 , 王显刚 , 王瑞山 , 等 . 老年急性冠状动脉综合征患者CRP与TNF-α、IL-1β相关性研究 [J ] . 中国病理生理杂志 , 2003 ( 10 ): 125 - 126 .

刘清霞 , 张宏颖 , 徐利霞 , 等 . 动脉粥样硬化斑块中TNF-α的表达与斑块稳定性的关系 [J ] . 中国循证心血管医学杂志 , 2019 , 11 ( 4 ): 441 - 444 .

张琼 , 万昌武 , 于燕妮 , 等 . 组织蛋白酶C和肿瘤坏死因子α在人冠脉组织中的表达及其与冠心病的相关性研究 [J ] . 中国病理生理杂志 , 2020 , 36 ( 12 ): 2133 - 2138 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Tongue image characteristics of phlegm-blood stasis syndrome in stable angina pectoris of coronary heart disease and influencing factors

Clinical diagnostic value of inflammatory markers in toxic pathogen syndrome of coronary heart disease with heart failure

Research on the correlation between TCM syndromes and comorbidities in patients with hypertension

Study on serum bile acid profile of coronary heart disease combined with paroxysmal atrial fibrillation patients with stagnant phlegm syndrome based on targeted metabolomics

Effect of Qiting Lishui Prescription on clinical efficacy, quality of life and serum matrix metalloproteinases in patients with coronary heart disease and heart failure

Related Author

LI Qiuyan

LOU Taiwei

WANG Zongxue

XU Yuying

ZHANG Jiwei

GUO Yuchen

SONG Tingting

GU Jiyu

Related Institution

Hospital of Nanjing University of Aeronautics and Astronautics

Institute of Microelectronics， Chinese Academy of Sciences

Blood Supply Department， Beijing Red Cross Blood Center

Department of General Internal Medicine， Xiyuan Hospital， China Academy of Chinese Medical Sciences

Department of Cardiovascular Medicine， Dongzhimen Hospital， Beijing University of Chinese Medicine

⁰

Clinical effect of Shenyuan Pills on coronary heart disease patients after PCI and its impact on inflammatory responses

DOI：10.16025/j.1674-1307.2025.12.002

摘要

Abstract

关键词

Keywords

references